Abemaciclib-induced lung damage leading to discontinuation in brain metastases from breast cancer: A case report  

作　　者：Hiroyasu Yamashiro Nao Morii 

机构地区：[1]Department of Breast Surgery,Tenri Hospital,Nara,Tenri 632-8552,Japan

出　　处：《World Journal of Clinical Cases》2023年第35期8425-8430,共6页世界临床病例杂志

摘　　要：BACKGROUND This case report addresses the dearth of effective therapeutic interventions for central nervous system metastases in patients with HER2-negative breast cancer.It presents a unique case of a woman with estrogen receptor-positive,HER2-negative breast cancer who developed brain metastasis.The report highlights her initial favorable response to abemaciclib and letrozole therapy prior to the discon-tinuation due to drug-induced lung damage(DILD).CASE SUMMARY In this comprehensive case summary,we present the clinical course of a woman in her 60s,who 11 years following primary breast cancer surgery,was diagnosed with multiple brain metastases.As a third-line systemic therapy,she underwent treatment with abemaciclib and letrozole.This treatment approach yielded a near-partial response in her metastatic brain lesions.However,abemaciclib adminis-tration ceased due to the emergence of DILD,as confirmed by a computed tomography scan.The DILD improved after 1 mo of cessation.Despite ongoing therapeutic efforts,the patient’s condition progressively deteriorated,ultimately resulting in death due to progression of the brain metastases.CONCLUSION This case underscores the challenge of managing adverse events in responsive brain metastasis patients,given the scarcity of therapeutic options.

关 键 词：Breast cancer HER2 negative Brain metastasis Abemaciclib Drug-induced interstitial lung damage Case report 

分 类 号：R73[医药卫生—肿瘤]